A Phase II Trial Measuring the Integration of Stereotactic Radiation Therapy Plus Surgery in Early Non-Small Cell Lung Cancer
Stereotactic ablative radiation therapy (SABR) is a new radiation treatment that delivers
high-dose, precise radiation to small tumours in 1-3 weeks of treatment.
The study combines SABR and surgery to treat non-small cell lung cancer. SABR will be done
first, with surgery done approximately 10 weeks later. There will be some extra imaging done
before and after the SABR.
The purpose of this study is to determine how effective SABR is in killing the cancer cells,
and if SABR can help make surgery more effective.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society